Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Why TEM stock sentiment could hinge on Tempus AI’s FDA-approved diagnostics expansion Find out how Tempus AI’s xT CDx approval could strengthen TEM stock sentiment, oncology diagnostics growth, and ADLT pricing strategy. bySoujanya RaviJune 6, 2026